Works matching IS 22351795 AND DT 2024 AND VI 13 AND IP 6

Results: 14

Contents Vol. 13, 2024.

Published in:: Liver Cancer (2235-1795), 2024, v. 13, n. 6, p. I, doi. 10.1159/000542824
Publication type:: Article

Front & Back Matter.

Published in:: Liver Cancer (2235-1795), 2024, v. 13, n. 6, p. 1, doi. 10.1159/000543199
Publication type:: Article

Challenges in Adjuvant Immunotherapy after Resection or Ablation for Hepatocellular Carcinoma at High-Risk of Recurrence.

Published in:

Liver Cancer (2235-1795), 2024, v. 13, n. 6, p. 573, doi. 10.1159/000542221

By:

Kudo, Masatoshi

Publication type:

Article

Acknowledgement to Reviewers.

Published in:: Liver Cancer (2235-1795), 2024, v. 13, n. 6, p. 675, doi. 10.1159/000542146
Publication type:: Article

Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma with Main Trunk and/or Contralateral Portal Vein Invasion in IMbrave150.

Published in:

Liver Cancer (2235-1795), 2024, v. 13, n. 6, p. 655, doi. 10.1159/000539897

By:

Finn, Richard S.;
Galle, Peter R.;
Ducreux, Michel;
Cheng, Ann-Lii;
Reilly, Norelle;
Nicholas, Alan;
Hernandez, Sairy;
Ma, Ning;
Merle, Philippe;
Salem, Riad;
Li, Daneng;
Breder, Valeriy

Publication type:

Article

Cost-Effectiveness of a Biomarker-Based Screening Strategy for Hepatocellular Carcinoma in Patients with Cirrhosis.

Published in:

Liver Cancer (2235-1795), 2024, v. 13, n. 6, p. 643, doi. 10.1159/000539895

By:

Singal, Amit G.;
Chhatwal, Jagpreet;
Parikh, Neehar;
Tapper, Elliot

Publication type:

Article

LI-RADS Category Can Be a Post-Surgical Prognostic Factor for Intrahepatic Cholangiocarcinoma in Patients with Liver Cirrhosis or Chronic Hepatitis B.

Published in:

Liver Cancer (2235-1795), 2024, v. 13, n. 6, p. 629, doi. 10.1159/000539794

By:

Park, Sungeun;
Koo, Boyeon;
Jeong, Boryeong;
Choi, Sang Hyun;
Lee, Jeong Min

Publication type:

Article

Prognostic Efficacy of the Albumin-Bilirubin Score and Treatment Outcomes in Hepatocellular Carcinoma: A Large-Scale, Multi-Center Real-World Database Study.

Published in:

Liver Cancer (2235-1795), 2024, v. 13, n. 6, p. 610, doi. 10.1159/000539724

By:

Kim, Kyu-Pyo;
Kim, Kang Mo;
Ryoo, Baek-Yeol;
Choi, Won-Mook;
Cha, Won Chul;
Kang, Mira;
Sinn, Dong Hyun;
Goh, Myung Ji;
Kim, Do Young;
Lee, Min Ji;
Lim, Subin;
Kim, DongKyu;
Baek, Kyoungdae;
Kim, Joohyun;
Choi, Eui Jun;
Lee, Doik;
Kim, Jung-Ae;
Kim, Ki-Hun

Publication type:

Article

Risk of Bleeding in Hepatocellular Carcinoma Patients Treated with Atezolizumab/Bevacizumab: A Systematic Review and Meta-Analysis.

Published in:

Liver Cancer (2235-1795), 2024, v. 13, n. 6, p. 590, doi. 10.1159/000539423

By:

Song, Young-Gi;
Yeom, Kyeong-Min;
Jung, Eun Ae;
Kim, Sang Gyune;
Kim, Young Seok;
Yoo, Jeong-Ju

Publication type:

Article

Clinical Utility of the Novel Oncological Criteria of Resectability for Advanced Hepatocellular Carcinoma.

Published in:

Liver Cancer (2235-1795), 2024, v. 13, n. 6, p. 601, doi. 10.1159/000539381

By:

Shindoh, Junichi;
Kawamura, Yusuke;
Akahoshi, Keiichi;
Matsumura, Masaru;
Okubo, Satoshi;
Akuta, Norio;
Tanabe, Minoru;
Kokudo, Norihiro;
Suzuki, Yoshiyuki;
Hashimoto, Masaji

Publication type:

Article

Reply to the Letter Regarding "Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study"

Published in:

Liver Cancer (2235-1795), 2024, v. 13, n. 6, p. 671, doi. 10.1159/000539205

By:

Kudo, Masatoshi;
Tsuchiya, Kaoru;
Yamashita, Tatsuya;
Koga, Hironori;
Nakagawa, Yuki;
Ikeda, Masafumi

Publication type:

Article

Oncological Resectability Criteria for Hepatocellular Carcinoma in the Era of Novel Systemic Therapies: The Japan Liver Cancer Association and Japanese Society of Hepato-Biliary-Pancreatic Surgery Expert Consensus Statement 2023.

Published in:

Liver Cancer (2235-1795), 2024, v. 13, n. 6, p. 579, doi. 10.1159/000538627

By:

Akahoshi, Keiichi;
Shindoh, Junichi;
Tanabe, Minoru;
Ariizumi, Shunichi;
Eguchi, Susumu;
Okamura, Yukiyasu;
Kaibori, Masaki;
Kubo, Shoji;
Shimada, Mitsuo;
Taketomi, Akinobu;
Takemura, Nobuyuki;
Nagano, Hiroaki;
Nakamura, Masafumi;
Hasegawa, Kiyoshi;
Hatano, Etsuro;
Yoshizumi, Tomoharu;
Endo, Itaru;
Kokudo, Norihiro

Publication type:

Article

Letter regarding "Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study"

Published in:

Liver Cancer (2235-1795), 2024, v. 13, n. 6, p. 669, doi. 10.1159/000538580

By:

Hatanaka, Takeshi;
Hiraoka, Atsushi;
Tada, Toshifumi;
Kakizaki, Satoru

Publication type:

Article

Erratum.

Published in:: 2024
Publication type:: Correction Notice